The accounting rules for intellectual property turn on one distinction: IP you develop internally is almost always expensed as you incur the costs, while IP you buy is capitalized as an asset at fair value and then either amortized or tested for impairment. That single rule shapes how patents, trademarks, copyrights, and trade secrets appear on your balance sheet, how they hit earnings, and how they generate tax deductions. Everything else in intellectual property accounting is a refinement of that split.
Classifying the IP Before You Book Anything
Classification comes first because it decides the asset’s useful life, and the useful life decides whether you amortize the asset or test it for impairment.
Patents give the holder exclusive rights to an invention or process. A utility or plant patent generally lasts 20 years from the U.S. filing date.1Office of the Law Revision Counsel. 35 USC 154 – Contents and Term of Patent That built-in expiration makes patents a finite-life asset.
Trademarks and trade names identify the source of goods or services and can be renewed indefinitely as long as the mark stays in active use. They are typically classified as indefinite-life, which means no amortization but annual impairment testing.
Copyrights protect original works of authorship. For works created after January 1, 1978, protection generally lasts for the life of the author plus 70 years.2Office of the Law Revision Counsel. 17 USC 302 – Duration of Copyright The legal life is long but finite, and the economic useful life is often much shorter.
Trade secrets cover proprietary information such as formulas, processes, or customer data. They have no statutory expiration, and protection lasts only as long as the owner keeps the information confidential. That makes their accounting life harder to pin down.
Business acquisitions surface additional identifiable intangibles: customer relationships, non-compete agreements, order backlogs. The finite-versus-indefinite line runs through all of them, and that line is what governs the accounting from here forward.
Internally Developed IP: Expense Now
Costs to develop IP inside the company generally must be expensed as incurred under U.S. GAAP. ASC Topic 730 sets this rule, and the IRS uses a similar framework for identifying qualifying R&D activity.3Internal Revenue Service. Appendix E – Directive Definitions The reasoning is conservatism: most research is too uncertain to be treated as an asset until someone else validates its value by paying for it.
The consequence is stark. A company can spend hundreds of millions producing a valuable drug or technology and record no asset for that spending. The economic value is real; GAAP simply refuses to recognize it until an arm’s-length transaction proves it.
Software Is the Main Exception
Internal-use software has its own rules under ASC 350-40, which splits development into three stages:
- Preliminary project stage: costs are expensed. This covers research, vendor evaluation, and feasibility.
- Application development stage: costs directly tied to building the software are capitalized once management commits to funding and the preliminary work is done. Coding, testing, and installation qualify. Training and data conversion do not.
- Post-implementation stage: costs are expensed again, including routine maintenance and user training after go-live.
Software built for sale or licensing to customers follows a separate standard, ASC 985-20. Capitalization cannot begin until the product reaches technological feasibility, typically shown by a detailed program design or a working model.4U.S. Securities and Exchange Commission. SEC EDGAR Filing – Software Development Costs Accounting Policy Everything before that point is expensed as R&D.
Patent Registration Costs Are Different
Legal fees and filing costs to register a patent can be capitalized even when the underlying invention was developed internally and all its R&D costs were expensed. Those registration costs secure the legal right itself, not the underlying research.5U.S. Securities and Exchange Commission. SEC EDGAR Filing – Intangible Assets Accounting Policy
Acquired IP: Capitalize at Fair Value
IP obtained by purchase or through a business combination goes on the balance sheet at fair value on the acquisition date. This applies to any intangible that arises from contractual or legal rights, or that can be separated from the business and sold on its own.
The initial recorded amount includes the purchase price plus directly attributable costs needed to put the asset into service, such as legal fees for due diligence and registration fees to transfer title.
In a business combination, the acquirer allocates the total purchase price across all identifiable assets based on their fair values. Anything that cannot be assigned to a specific identifiable asset becomes goodwill. How you split the price among the intangibles matters, because that split sets each asset’s amortization schedule and drives reported earnings for years.
Valuing Acquired IP
Fair value under ASC 820 is the price that would be received to sell the asset in an orderly transaction between market participants at the measurement date. Determining it usually requires a valuation specialist, who chooses among three approaches based on the asset and the data available.
The market approach uses recent arm’s-length transactions in comparable IP as reference points, adjusted for differences in size, age, and relevance. It is intuitive but rarely primary for unique IP, since most proprietary technology and distinctive brands lack a deep market of comparables. When solid transaction data exists, auditors give market-based values considerable weight because the inputs are observable.
The income approach is the workhorse for unique assets. It projects the future cash flows attributable to the IP and discounts them to present value. Discounted cash flow analysis isolates the incremental cash flows the IP generates and discounts them at a risk-adjusted rate. The relief-from-royalty method estimates what the company would pay to license the IP if it did not own it, applies a market royalty rate to projected revenues, and discounts the resulting royalty stream. The multi-period excess earnings method, common for customer-related intangibles, subtracts the returns attributable to all other contributing assets from total cash flows to isolate the residual earnings tied to the subject intangible. Every income method depends on projections and discount rates, and auditors examine both closely.
The cost approach estimates what it would cost to recreate the IP or build something with equivalent function, then reduces that figure for physical, functional, and economic obsolescence. It fits newer assets or those with unclear income potential, and it functions as a ceiling because a rational buyer would not pay more than the cost of replication. For established brands or proven technology, the cost approach usually understates fair value and only supports the primary method.
Amortizing Finite-Life IP
Patents, copyrights, and other IP with a determinable useful life are amortized over the period the asset is expected to contribute to cash flows. The useful life is the shorter of the legal life and the economic life. A patent with 18 years of remaining legal protection but 8 years of commercial relevance is amortized over 8 years.
Straight-line amortization is the default under ASC 350. A different pattern is permitted when the company can reliably show that the economic benefits are consumed unevenly, but most companies stay with straight-line because supporting an alternative pattern with evidence is difficult.
Impairment Testing
Finite-Life Assets
Finite-life IP does not need annual impairment testing. Testing is triggered when events or circumstances suggest the carrying amount may not be recoverable. Triggers include a major adverse shift in the business climate, a competitor’s technological breakthrough, or a significant drop in the asset’s market value.
When a trigger occurs, the test runs in three steps. First, confirm that impairment indicators are actually present. Second, run the recoverability test: compare the carrying amount to the total undiscounted future cash flows expected from using and eventually disposing of the asset. If undiscounted cash flows exceed the carrying amount, the asset passes and no loss is recognized, even if fair value has fallen below book value. Third, if the asset fails, measure the loss as the amount by which carrying value exceeds fair value. The loss hits the income statement immediately, and it cannot be reversed later under U.S. GAAP.
Indefinite-Life Assets
Indefinite-life IP, such as many trademarks, is never amortized but must be tested for impairment at least annually, and more often if conditions suggest impairment.6Financial Accounting Standards Board. Goodwill Impairment Testing The annual test compares fair value directly to carrying amount. If carrying amount is higher, the difference is recognized as an impairment loss.
Companies can perform a qualitative assessment first, sometimes called “Step Zero,” looking at macroeconomic conditions, industry trends, and company-specific events to judge whether it is more likely than not that fair value has dropped below carrying amount. If the qualitative screen shows no likely impairment, the full quantitative test can be skipped for the year. Goodwill follows a similar annual framework under ASC 350, comparing the reporting unit’s fair value to its carrying amount.
Tax Treatment Diverges From GAAP
Tax rules for IP often part ways with the accounting treatment, which is why deferred tax assets and liabilities show up on the balance sheet.
Acquired Intangibles Under Section 197
Most intangibles acquired as part of buying a business fall under IRC Section 197 and are amortized over a flat 15-year period starting in the month of acquisition. The list is broad: goodwill, going concern value, patents, copyrights, trademarks, customer-based intangibles, covenants not to compete, and government-granted licenses.7Office of the Law Revision Counsel. 26 USC 197 – Amortization of Goodwill and Certain Other Intangibles
The 15-year period is mandatory regardless of the asset’s actual useful life. A patent with 5 years of remaining legal protection still amortizes over 15 years for tax, while GAAP would amortize it over 5. A trademark that GAAP treats as indefinite-life still generates 15 years of tax deductions. Mismatches like these are among the most common sources of deferred tax items for companies with significant acquired IP.
Research and Experimental Expenditures Under Section 174
The rules here have moved twice in a few years. Before 2022, companies could generally deduct domestic R&D spending immediately. Legislation enacted in 2017 changed that, requiring domestic R&D costs to be capitalized and amortized over 5 years, and foreign research over 15 years, for tax years beginning after December 31, 2021.8Office of the Law Revision Counsel. 26 USC 174 – Amortization of Research and Experimental Expenditures
In 2025, Congress enacted Section 174A through the One Big Beautiful Bill Act, permanently restoring immediate expensing for domestic research and experimental expenditures for tax years beginning after December 31, 2024. Foreign R&D still has to be capitalized and amortized over 15 years. Software development costs are treated as R&D expenditures eligible for immediate expensing under the domestic rule.
For GAAP, internal R&D is expensed immediately under ASC 730. For tax, domestic R&D is immediately deductible again. The window from 2022 through 2024, when tax required capitalization while GAAP required expensing, created deferred tax assets that are still unwinding on many balance sheets.
Where IP Shows Up on the Statements
Intellectual property touches all three primary statements. On the balance sheet, IP appears as a non-current intangible asset, reported net of accumulated amortization and any recognized impairment losses. On the income statement, amortization typically sits within operating expenses, and impairment losses show up there or on a separate line depending on materiality. On the cash flow statement, buying IP is an investing outflow, while amortization is added back to net income in operating activities under the indirect method because it is non-cash.
Disclosures under ASC 350-30-50 do the heavy lifting for analysts. For finite-life intangibles, companies disclose the gross carrying amount and accumulated amortization for each major class, total amortization expense for the period, and estimated aggregate amortization expense for each of the next five fiscal years. For indefinite-life intangibles, the total carrying amount and a breakdown by major class are required.
When an impairment loss is recognized, the notes describe the impaired asset, the facts leading to impairment, the amount of the loss, the method used to determine fair value, and the income statement line where the loss appears. Companies also disclose their accounting policy for costs incurred to renew or extend the term of a recognized intangible asset.
If the estimated useful life of a finite-life intangible changes, ASC 250 treats it as a change in accounting estimate applied prospectively. The remaining carrying amount is amortized over the revised useful life going forward, with no restatement. If the revision also triggers an impairment loss, that loss is recognized right away.
One Boundary Worth Knowing: IFRS Development Costs
If you compare U.S. financial statements against companies reporting under IFRS, the internal development rule does not match. IAS 38 splits R&D into a research phase and a development phase.9IFRS Foundation. IAS 38 Intangible Assets Research is always expensed, matching U.S. GAAP. But development expenditure that meets specified criteria, including demonstrated technical feasibility, intent to complete the asset, and reliable cost measurement, must be capitalized as an intangible asset. Two companies running identical R&D programs can therefore report noticeably different assets and earnings depending only on which framework applies.